on a good broad overview of the history and current status of oral anticoagulant drugs. 1 In this regard, I would like to mention briefly some recent data that may be of interest to readers. Kant and colleagues2 have described the occurrence of warfarin-induced skin necrosis in relationship to peritoneal dialysis\p=m-\associated loss of protein S. It is suggested that these losses may become critical in certain settings and, hence, this complication must be kept in mind when managing the patients with peritoneal dialysis who receive warfarin therapy.Ansell discusses the prompt administration of vitamin K and the use of prostacyclin in the management of this condition. Some investigators3 have demonstrated the continuation or reinstitution of oral anticoagulant therapy in these patients without further skin involvement. It is postulated that, as skin necrosis occurs due to a more rapid reduction in protein C levels compared with other factors affected by oral anticoagulants, this temporary imbalance resolves as other coagulation factor levels also be¬ come depressed. This would explain why further skin ne¬ crosis has been shown not to occur in spite of continuing the medication. This interesting concept certainly war¬ rants further investigation.While oral anticoagulants are not recommended in any trimester of pregnancy, the role of these drugs in the nursing mother has been studied by two groups. In one study,4 warfarin was not detected either in the breast milk of 13 nursing mothers or in the plasma of any of seven infants tested. In the other,3 two breast-fed infants of nurs¬ ing mothers receiving oral anticoagulants were found to have 100% of control activity for prothrombin time and factors V, VII, and X. These studies suggest that oral an¬ ticoagulants may be used safely in the nursing mother as they are not present in breast milk and such use does not induce an anticoagulant effect in the breast-fed infant.